AJMC® in the Press, March 6, 2020

A study by S&P Global Ratings, titled “Biosimilar Adoption in the U.S. Will Challenge Some of Pharma’s Biggest Names,” referenced a study published in the June 2019 issue of Evidence-Based Oncology™. The study, “Addressing Oncologists' Gaps in the Use of Biosimilar Products,” found that the availability of biosimilar products may improve access to healthcare by increasing the number of therapeutic options available at potentially lower costs. A summary of the S&P Global Ratings study can be found here.

A piece published by The Heartland Institute cited a study published in the February 2015 issue of The American Journal of Managed Care^® (AJMC^®), “Leveraging Remote Behavioral Health Interventions to Improve Medical Outcomes and Reduce Costs.” Study authors discovered that successful patient engagement in a nationally available, remotely delivered behavioral health intervention can significantly improve medical outcomes and lower healthcare costs.

An article contributed to MenaFN.com, “Injectable Drug Delivery Market Is Projected to Reach $624.5 Billion by 2021,” highlighted a December 2017 supplement to AJMC^®, “Pricing and Contracting in Granulocyte Colony Stimulating Factors and Biosimilars for Febrile Neutropenia.” The study authors indicated that “biosimilars can offer an opportunity in terms of cost-saving potential, with an estimated potential of $44.2 billion in savings in biologic drug spending in the United States from 2014 to 2024.”

An article published on AJMC.com, titled “Sleep Disorders Common in Patients With T1D, Review Shows,” was cited by diabetes.co.uk, which detailed the review’s findings that while there are consistent identifiable links between sleep problems and health outcomes in patients with type 1 diabetes, there are no screening recommendations related to sleep in these patients.